FTC - Federal Trade Commission
06/18/2026 | Press release | Distributed by Public on 06/18/2026 11:20
Aurobindo-Lannett, In the Matter of - The FTC is requiring Aurobindo Pharma Limited to divest four different generic drug products to complete its $250 million acquisition of[...]
Last Updated
June 18, 2026
Case Status
Pending
In the Matter of Aurobindo Pharma LTD, a corporation; Aurobindo USA Inc., a corporation; and Lannett Company, Inc., a corporation.
FTC Matter/File Number
251 0096
Docket Number
C-4834
Enforcement Type
Part 2 Consents
Case Summary
The FTC is requiring Aurobindo Pharma Limited to divest four different generic drug products to complete its $250 million acquisition of Lannett Company Inc.
Case Timeline
June 18, 2026
File
Agreement Containing Consent Order (128.68 KB)
File
Complaint (147.08 KB)
File
Order to Maintain Assets (207.94 KB)
File
Decision and Order (390.84 KB)
FTC - Federal Trade Commission published this content on June 18, 2026, and is solely responsible for the information contained herein. Distributed via Public Technologies (PUBT), unedited and unaltered, on June 18, 2026 at 17:20 UTC. If you believe the information included in the content is inaccurate or outdated and requires editing or removal, please contact us at [email protected]